Literature DB >> 22741587

A monoclonal antibody SZ-117 that recognizes filamin A derived from tumor cells.

Zibin Bu1, Ruifang Liu, Bingxue Shang, Zhifei Cao, Yanyan Pan, Quansheng Zhou, Changgeng Ruan.   

Abstract

SZ117 is a monoclonal antibody against matrix metalloproteinase-2 (MMP-2) and exhibits anti-tumor angiogenic effect. In this study, we observed that SZ117 bound to a 280 kDa protein, which was detected in tumor cell-derived Matrigel and various tumor cells. Using immunoprecipitation, mass spectrometry analysis, and Western blot analysis, we identified the 280 kDa protein as filamin A and found that filamin A and its degraded products, notably a 53 kDa fragment, were released from a variety of tumor cells. This suggests that SZ117 is useful in the study of the pathogenesis of filamin A and that blockage of filamin A by SZ117 might contribute to the anti-tumor angiogenic effect of the monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22741587      PMCID: PMC3386001          DOI: 10.1089/hyb.2011.0109

Source DB:  PubMed          Journal:  Hybridoma (Larchmt)        ISSN: 1554-0014


  12 in total

1.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Authors:  L G Presta; H Chen; S J O'Connor; V Chisholm; Y G Meng; L Krummen; M Winkler; N Ferrara
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

2.  Phospholipid scramblase 1 binds to the promoter region of the inositol 1,4,5-triphosphate receptor type 1 gene to enhance its expression.

Authors:  Quansheng Zhou; Iris Ben-Efraim; Jo-Lawrence Bigcas; Daniela Junqueira; Therese Wiedmer; Peter J Sims
Journal:  J Biol Chem       Date:  2005-08-09       Impact factor: 5.157

3.  Normal hemostasis but defective hematopoietic response to growth factors in mice deficient in phospholipid scramblase 1.

Authors:  Quansheng Zhou; Ji Zhao; Therese Wiedmer; Peter J Sims
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

4.  Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.

Authors:  Ozge Alper; William G Stetler-Stevenson; Lyndsay N Harris; Wolfgang W Leitner; Metin Ozdemirli; Dan Hartmann; Mark Raffeld; Mones Abu-Asab; Stephen Byers; Zhengping Zhuang; Edward H Oldfield; Yanhe Tong; Elke Bergmann-Leitner; Wayne E Criss; Koichi Nagasaki; Samuel C Mok; Daniel W Cramer; F Seyda Karaveli; Raphaela Goldbach-Mansky; Paul Leo; Kurt Stromberg; Robert J Weil
Journal:  Cancer Sci       Date:  2009-06-17       Impact factor: 6.716

Review 5.  III. Angiogenesis: complexity of tumor vasculature and microenvironment.

Authors:  Mitsuko Furuya; Yoshikazu Yonemitsu; Ichiro Aoki
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 6.  Revisiting the seed and soil in cancer metastasis.

Authors:  Martin Mendoza; Chand Khanna
Journal:  Int J Biochem Cell Biol       Date:  2009-02-03       Impact factor: 5.085

Review 7.  Anticancer strategies involving the vasculature.

Authors:  Victoria L Heath; Roy Bicknell
Journal:  Nat Rev Clin Oncol       Date:  2009-05-07       Impact factor: 66.675

Review 8.  Ancestral vascular tube formation and its adoption by tumors.

Authors:  Tomás Kucera; Eckhard Lammert
Journal:  Biol Chem       Date:  2009-10       Impact factor: 3.915

Review 9.  Tumor microenvironment and angiogenesis.

Authors:  Pia Nyberg; Tuula Salo; Raghu Kalluri
Journal:  Front Biosci       Date:  2008-05-01

Review 10.  The discovery of antiangiogenic molecules: a historical review.

Authors:  Domenico Ribatti
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more
  1 in total

1.  Targeting filamin B induces tumor growth and metastasis via enhanced activity of matrix metalloproteinase-9 and secretion of VEGF-A.

Authors:  S Bandaru; A-X Zhou; P Rouhi; Y Zhang; M O Bergo; Y Cao; L M Akyürek
Journal:  Oncogenesis       Date:  2014-09-22       Impact factor: 7.485

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.